Ototoxic Medications: The Complete List (and What to Do If You Are Taking One)

Ototoxicity is drug-induced damage to the cochlea (hearing), vestibular apparatus (balance), or auditory nerve. Roughly 200 medications carry documented ototoxic potential. In Indian practice, four drug classes account for the overwhelming majority of clinically significant ototoxic hearing loss: aminoglycoside antibiotics, platinum-based chemotherapy, loop diuretics, and high-dose salicylates.

The typical pattern is bilateral, symmetric, high-frequency-first sensorineural loss — indistinguishable audiometrically from noise or age-related loss unless the clinician knows to look for the drug link. Some cases are reversible on drug discontinuation (salicylates, some diuretic use); most aminoglycoside and cisplatin-related loss is permanent.

Amikacin, gentamicin, streptomycin, tobramycin, kanamycin and neomycin all cause cumulative cochlear hair-cell damage. In India, streptomycin is still widely used in second-line tuberculosis regimens, and gentamicin is a workhorse in neonatal sepsis and complicated urinary tract infections. Cumulative dose, duration >7–14 days, renal impairment, existing hearing loss and concurrent loop diuretic use are the major risk factors.

Best-practice monitoring is a baseline audiogram before any planned aminoglycoside course longer than 5 days, weekly high-frequency audiograms during treatment, and a follow-up audiogram 4–6 weeks after completion. This is standard at AIIMS and PGIMER but under-utilised at district hospital level. Genetic predisposition (mitochondrial m.1555A>G mutation, common in some South Asian populations) causes profound loss after even a single aminoglycoside dose — screening is available and rapidly becoming affordable.

Cisplatin causes measurable hearing loss in 60–75% of patients receiving standard oncology regimens. Loss is bilateral, high-frequency-first, dose-dependent and largely irreversible. Carboplatin is less ototoxic per gram but often given at higher cumulative doses. Head-and-neck, testicular, ovarian, cervical, lung and paediatric solid-tumour patients are commonly affected.

Every oncology patient starting a platinum regimen should have a baseline high-frequency audiogram, a mid-course audiogram, and post-treatment audiograms at 3 and 12 months. Sodium thiosulphate — a rescue agent — is FDA-approved for reducing ototoxicity in paediatric localised cancers. Once loss is established, hearing rehabilitation with Signia Styletto IX or higher tiers (5IX/7IX) is standard, and the emotional support of restoring speech clarity to a cancer survivor is often as valuable as the audibility gain.

Loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid) cause dose-related, usually reversible hearing loss with tinnitus, especially at high IV doses in cardiac failure or renal impairment. Reduction of dose or switch to alternatives usually reverses the loss.

Salicylates (aspirin at high anti-inflammatory doses) cause reversible bilateral high-frequency loss with tinnitus. Discontinuation typically restores hearing within 24–72 hours.

Antimalarials — quinine and chloroquine at anti-arrhythmic or high antimalarial doses — cause tinnitus and reversible loss.

NSAIDs, macrolide antibiotics, quinolones — occasional ototoxic reports; monitoring recommended if hearing changes emerge.

Immunosuppressants and biologicals — rare but documented ototoxicity in some newer oncology and inflammatory agents; oncologists now routinely include audiogram screening for high-risk regimens.

1. Do not stop your medication without discussing with the prescribing doctor. Untreated TB or cancer is far more dangerous than the associated ototoxicity risk.
2. Ask for a baseline audiogram before starting any planned long course, and repeat serial audiograms during and 6 weeks after treatment. Every HearClear clinic provides free-of-charge oncology and TB ototoxicity monitoring audiograms.
3. Report tinnitus, ear fullness, dizziness or subjective hearing change immediately — do not wait for the next scheduled test.
4. Avoid additive ototoxic exposures — loud noise, other ototoxic drugs, and dehydration all magnify the effect.
5. Consider genetic screening for m.1555A>G if you have a family history of hearing loss after antibiotic exposure or belong to a high-prevalence community.
6. Once loss is stable, discuss hearing rehabilitation — Signia Styletto IX 3IX/5IX/7IX tiers with tinnitus-masking programs are our most common prescription for adult ototoxic loss.

If any of the above matches your experience, book a free clinical hearing assessment. Our Signia Certified audiologists are RCI-registered and offer home visits across 195+ Indian cities — the audiogram is diagnostic and always free.

This article is a plain-language summary reviewed against ASHA (American Speech-Language-Hearing Association), IJOHNS (Indian Journal of Otolaryngology and Head & Neck Surgery), BSA (British Society of Audiology) and Signia clinical documentation. It is educational only. Any concerning symptoms warrant an in-person evaluation by an ENT physician and an RCI-registered audiologist.